MGF
A splice variant of IGF-1 produced in response to mechanical stress on muscles, promoting satellite cell activation and muscle repair.
MGF is a fragment of IGF-1 that muscle makes for itself when you load it hard. The theory is that injecting it after a workout amplifies the stem-cell signal that repairs and grows the muscle. The biology behind that theory is real and traces to Geoffrey Goldspink's lab in the 1990s, but it has never been tested in a human trial — there is no clinical efficacy data, no human dosing study, and the receptor it is supposed to act on has never been pinned down. It also falls apart in solution within hours, and it is banned at all times in sport.
What is MGF?
MGF (Mechano Growth Factor) is a splice variant of IGF-1 (specifically the Ec isoform in humans) that is produced locally in muscle tissue in response to mechanical loading (exercise). It activates muscle satellite (stem) cells, initiating muscle repair and growth. Synthetic MGF is widely said to have a half-life of minutes, but no measured figure has ever been published for it in humans or animals — the literature offers a prediction, not a measurement.
What MGF Is Investigated For
MGF is used almost exclusively in bodybuilding circles for post-workout satellite cell activation and localized muscle repair, built on Geoffrey Goldspink's 1990s discovery that mechanical loading produces a distinct IGF-1 splice variant (IGF-1Ec) with a unique C-terminal E-domain that activates muscle stem cells. The strongest evidence is mechanistic and preclinical — MGF's role in load-gated satellite cell proliferation before differentiation is reasonably well-characterized in vitro and in rodent models. Human clinical evidence for synthetic MGF is essentially absent: no Phase 2 or 3 trials for any indication, no pharmacokinetic or dose-ranging data in humans, and the specific receptor mediating E-domain effects remains incompletely characterized. Practical use is further complicated by MGF's extreme instability in solution (activity lost within hours to a day) and the fact that PEG-MGF, which solves stability, changes the pharmacology away from the localized pulsatile mechanism that motivated the peptide in the first place. The sharper problem is not thin replication — the load-induced splicing response has been reproduced independently in Copenhagen, Baylor, Milan and NIOSH laboratories — but that the peptide itself has never been found. An independent NIH-funded review concluded that no analogous peptide product of the IGF-1 gene has been identified in or isolated from cultured cells, their conditioned medium, or any in vivo animal tissue or biological fluid. The mRNA is real and reproducible; the protein that injectable MGF is meant to imitate remains hypothetical, which makes this one of the more mechanistically speculative growth-factor peptides in common use.
History & Discovery
Mechano Growth Factor was characterized in the 1990s by Geoffrey Goldspink and colleagues at the Royal Free & University College London Medical School, who showed that mechanical loading of skeletal muscle produces an alternatively spliced IGF-1 transcript — IGF-1Ec in humans, IGF-1Eb in rodents — distinct from the systemic liver-derived IGF-1Ea isoform. Their central insight was that the local muscle response to loading and damage is not simply a spillover of hepatic IGF-1 but a distinct, mechanically gated splicing event producing a peptide with a unique C-terminal E-domain. Goldspink's group proposed that this E-domain activates satellite cells and expands the muscle stem-cell pool before the IGF-1 portion, once cleaved, drives downstream differentiation and hypertrophy. Synthetic MGF — typically the isolated E-domain sequence or the intact IGF-1Ec analogue — followed into research supply in the 2000s, and a PEGylated variant (PEG-MGF) was developed specifically to address MGF's intrinsic instability. Bodybuilding-market adoption arrived soon after, with the positioning that post-workout MGF injection would amplify the mechanically triggered satellite cell response. Published human data on synthetic MGF remains sparse; most evidence is in vitro or rodent, and the precise receptor mediating E-domain effects has been debated rather than definitively characterized. No therapeutic development program has advanced MGF toward regulatory approval. Dominikowski and colleagues (Front Endocrinol 2026, PMID 42395176) situated the molecule within the broader landscape of performance-enhancing peptides modulating the GH-IGF1 axis, characterizing the persistent clinical-evidence-versus-self-administration gap that defines its contemporary use in wellness and bodybuilding communities. Their tiering applies specifically to PEG-MGF, which they place in the lowest evidence tier with no peer-reviewed human studies and no reported half-life.
How It Works
When you exercise hard, your muscles naturally produce MGF to activate stem cells that repair and grow muscle tissue. Synthetic MGF aims to amplify this natural repair signal.
MGF is produced by alternative splicing of the IGF-1 gene in response to mechanotransduction. The unique C-terminal E-domain peptide activates muscle satellite cells and promotes their proliferation without premature differentiation. The mechanism by which it does so is genuinely unsettled. The widely repeated claim that it signals through a receptor other than IGF-1R rests on one 2002 experiment in which blocking IGF-1R with an antibody failed to abolish the E-domain effect — an inference that a different receptor exists, not an identification of one, and in the two decades since, no candidate receptor has been named. Independent work has since shown the picture is also form-dependent: full-length MGF directly activates IGF-1R and both insulin receptor isoforms with near-IGF-I potency at high concentrations, while the isolated E-peptide does not. Other groups have proposed the E-domain acts intracellularly, trafficking to the nucleus rather than engaging a surface receptor at all. This expands the satellite cell pool before IGF-1Ea (the systemic isoform) drives their differentiation into mature myofibers. MGF also has neuroprotective properties through similar stem cell activation in neural tissue.
Evidence Snapshot
Human Clinical Evidence
Very limited. Primarily studied in exercise physiology research.
Animal / Preclinical
Moderate. Satellite cell activation and muscle repair demonstrated in animal models.
Mechanistic Rationale
Moderate. MGF-specific receptor and signaling are still being fully characterized.
Research Gaps & Open Questions
What the current literature has not yet settled about MGF:
- 01No human clinical trials of synthetic MGF for any indication — the entire translation from Goldspink's splicing biology to injectable-peptide use rests on preclinical and in vitro data.
- 02Receptor identity and pharmacology — the specific receptor for the isolated E-domain remains incompletely characterized; whether synthetic E-domain peptides engage that receptor in humans with the kinetics implied by the mechanism is not firmly established.
- 03Pharmacokinetics — there is no published half-life for synthetic MGF or PEG-MGF in any species. The ubiquitous figure of minutes traces to a predicted value, not a measured one, and the proportion of an injected dose that reaches and activates target tissue before degradation has never been quantified.
- 04Comparative effect of MGF versus PEG-MGF in humans — PEGylation extends half-life but may alter the mechanistic premise (mechanically localized, acutely timed response); head-to-head human data is absent.
- 05Independent replication — the MGF mechanistic framework is strongly associated with Goldspink's research program, and independent replication of key findings in other labs and species is thinner than would be ideal.
- 06Long-term local muscle tissue effects — repeated IM injection of a satellite-cell-activating peptide into the same muscle could plausibly affect fiber-type composition, fibroblast activity, or fibrotic change; no systematic human study exists.
Forms & Administration
IM injection into target muscle immediately after training. Typical research dose: 100-200mcg per site. Must be used within minutes of reconstitution due to instability. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Community protocols most commonly describe 100–200 mcg per injection site, sometimes up to 400 mcg when multiple muscle groups are targeted across a session. These figures are convention from online sources, not clinical evidence — no human dose-ranging study of synthetic MGF has been conducted.
Frequency
Post-workout intramuscular injection into the trained muscle is the standard described cadence, because the mechanistic rationale — amplifying the load-triggered satellite cell response — depends on proximity to mechanically damaged tissue. Injection is typically timed within minutes to an hour of training. Non-training days are usually skipped. PEG-MGF, by contrast, is dosed less frequently (2–3x weekly) and without the strict post-workout timing because of its extended half-life.
Timing Considerations
Time of day
Ties to training schedule rather than clock time.
Relative to meals
Often paired with a post-workout protein-and-carbohydrate meal.
Relative to exercise
Injected post-workout into the trained muscle group, typically within 30–60 minutes of training. MGF is mechano-growth factor — the biological rationale is that muscle damage from training opens the window where its myogenic signaling is most active, so injection timing tracks that window tightly.
Cycle Length
4–6 weeks on, 4 weeks off is the most commonly described cycling pattern. Rationale offered in the community is satellite-cell response saturation and general caution about chronic supraphysiologic growth-factor exposure. These are not derived from human trial data.
Protocol Notes
Synthetic MGF is notoriously unstable in solution. Reconstituted peptide loses activity within hours to a day at room temperature, and community practice reflects this: reconstitute immediately before injection, or store reconstituted product cold and use within a short window. PEG-MGF addresses this with a polyethylene glycol modification that meaningfully extends both shelf life and circulating half-life, at the cost of the strict post-workout localization rationale. Intramuscular injection into the belly of the trained muscle using a small-gauge insulin syringe is the convention. As with DES, repeated injection into the same site risks local fibrosis and infection, and site rotation across training sessions is standard practice. All of the above describes community convention, not validated human protocols. Most published MGF evidence is preclinical. Synthesis quality is a practical concern — the correct IGF-1Ec E-domain sequence versus truncated, misfolded, or mis-sequenced product is not reliably verified in the research-chemical market.
These numbers describe community practice, not a prescription. Synthetic MGF is not FDA-approved for any indication. Most evidence is preclinical. Any actual use should be under the direct supervision of a qualified healthcare provider.
Timeline of Effects
Onset
Users commonly describe enhanced post-workout fullness and perceived recovery at the injected muscle within the first 1–2 training sessions. These reports are anecdotal. Published preclinical satellite cell proliferation kinetics operate over days, not hours, so acute subjective effects may not map cleanly onto the proposed mechanism.
Peak Effect
Reported hypertrophy and strength effects, where described, are most often in the 3–6 week window of a typical cycle, overlapping with the normal adaptation timeframe of resistance training. No human trial has isolated the MGF-specific contribution from training alone.
After Discontinuation
Unmodified MGF clears within hours after the last dose; PEG-MGF clears over days. Training-driven adaptations persist to the degree that training, nutrition, and recovery persist. The satellite-cell pool expansion proposed by Goldspink would, if real at pharmacologic doses, presumably leave some durable substrate for subsequent hypertrophy, but this has not been demonstrated in humans.
Common Questions
What's the difference between MGF and PEG-MGF?
PEG-MGF carries a polyethylene glycol modification that slows its clearance, so it distributes systemically and is dosed every few days instead of immediately after a session. Unmodified MGF is used for localized effects at the injection site. The commonly repeated figures — minutes for MGF, hours for PEG-MGF — are community convention rather than measured pharmacokinetics; no published study reports a half-life for either, and a 2026 review of GH-axis performance peptides states explicitly that PEG-MGF's half-life is not reported. The practical difference that is real is stability in solution, which PEGylation genuinely improves.
Is there any human clinical trial evidence for synthetic MGF?
Effectively no. There are no Phase 2 or 3 trials of synthetic MGF for any indication, no human pharmacokinetic or dose-ranging studies, and no head-to-head data comparing MGF and PEG-MGF in people. The mechanistic case rests on Geoffrey Goldspink's splicing biology and rodent and in-vitro satellite-cell work from the 1990s and 2000s. The splicing part has been replicated independently; what has not been demonstrated by anyone, including Goldspink's own group, is that the corresponding E-peptide protein actually exists in tissue. Treat any confident claims about human efficacy as extrapolation, not evidence.
Does MGF carry the same cancer concern as IGF-1 LR3?
For the full-length form, yes, and more directly than the usual framing admits. The reassurance offered for MGF is that it acts through some receptor other than IGF-1R, so it supposedly avoids the proliferative signalling that makes IGF-1 analogs worrying. Independent work has shown that this is only true of the short isolated E-peptide. Full-length MGF — which is what a good deal of research-chemical product actually is — directly activates IGF-1R with roughly IGF-I-like maximal effect at high equimolar concentrations, and activates both insulin receptor isoforms as well. Since buyers generally cannot verify which form they have received, the prudent assumption is that the IGF-1R-mediated risk profile applies.
Why does MGF have to be injected right after a workout?
The mechanistic premise is that mechanical loading triggers the local IGF-1Ec splice variant, opening a window where satellite-cell signaling is most active. Community practice mirrors this — injection into the trained muscle within 30–60 minutes of the session, on training days only. Unmodified synthetic MGF is also assumed to clear within minutes — predicted rather than measured — so the reasoning is that it has to be near its target tissue almost immediately to do anything. PEG-MGF relaxes the timing because of its extended half-life, but at the cost of the localized-pulse rationale.
Is MGF banned in sports?
Yes. WADA's S2.3 (growth factors and growth factor modulators) names 'mechano growth factors (MGFs)' on both the 2026 and 2027 lists, prohibited at all times, in and out of competition, and that covers MGF and PEG-MGF. Mass-spectrometric detection methods for MGF specifically have been published in the doping-control literature, so the assumption that it is undetectable is outdated. Athletes subject to WADA, USADA, UKAD, or equivalent national frameworks should treat both forms as categorically banned.
Who MGF Is NOT For
- •Active or recent-history cancer, particularly any muscle-origin or growth-factor-sensitive malignancy — MGF's satellite-cell activation and IGF-1R signaling raise theoretical tumor-promotion concerns that are not quantified in humans.
- •Pregnancy and breastfeeding — no safety data; growth factor signaling in developmental contexts is not a place to extrapolate.
- •Pediatric use (under 18) — no appropriate indication; skeletal muscle development and growth-plate biology involve the endogenous IGF-1 system already.
- •Known hypersensitivity to peptide therapeutics, excipients used in reconstitution, or PEG (for PEG-MGF specifically — PEG hypersensitivity is documented).
- •Active infection or significant scar tissue at the planned injection site.
- •Active acromegaly or untreated pituitary disorder — adding exogenous growth factor signaling is contraindicated.
Drug & Supplement Interactions
Clinical interaction data for synthetic MGF is absent; what follows is mechanistic extrapolation. Concurrent use with growth hormone, GH secretagogues (sermorelin, CJC-1295, ipamorelin, tesamorelin), MK-677, IGF-1 LR3, or IGF-1 DES compounds IGF-1 axis activation and may meaningfully raise systemic IGF-1 tone beyond what any single agent produces. The cardiovascular, glycemic, and cancer-risk implications of combined use are not characterized. Corticosteroids can blunt satellite cell response and may antagonize the proposed MGF mechanism. NSAIDs have been shown in some studies to attenuate post-exercise satellite cell activation; whether this meaningfully affects MGF response is unknown but plausible. Patients on IGF-1R-directed oncology therapies should not use MGF. Anabolic-androgenic steroids do not directly interact with the E-domain pathway but share cardiovascular and cancer-risk considerations. PEG-MGF specifically carries PEG-related interaction concerns — documented PEG hypersensitivity cross-reactivity with other PEGylated therapeutics (certain monoclonals, some vaccines) is worth disclosing to prescribing clinicians.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved
- • Very limited human data
- • Extremely short half-life limits practical use
- • Must be injected immediately post-workout for best effect
What We Don't Know
Human safety profile is essentially unknown. Theoretical concerns about uncontrolled satellite cell activation.
Legal Status
United States
Synthetic MGF is not FDA-approved for any medical indication. It is sold through research-chemical channels labeled 'not for human use'; distribution for human consumption is unauthorized under the FD&C Act. It is not a scheduled controlled substance. On FDA's list of bulk substances nominated for 503A compounding (updated May 14, 2026), mechano growth factor (MGF) sits in Category 3 — nominated without adequate support — so it is neither on the 503A bulks list nor under evaluation for it. The pegylated form is handled differently again: PEG-MGF does not appear in the 503A category list at all, and instead sits in the nominated-but-withdrawn table on FDA's Category 2 safety-risk page, where the agency notes it has identified no human exposure data for PEG-MGF by any route and flags immunogenicity risk. Neither form is covered by the October 2026 HHS enforcement-discretion policy for compounded peptides, which names only six substances.
International
Not authorized as a medicine in the EU, UK, Canada, or Australia. Australian TGA treats it as a Schedule 4 prescription-only substance. European and other developed-market regulatory posture mirrors the US in treating it as an unapproved investigational agent.
Sports & Competition
Prohibited at all times under WADA S2.3 (growth factors and growth factor modulators), which names mechano growth factors (MGFs) on both the 2026 list and the 2027 list in force from January 1, 2027. Although WADA assays have historically been best-developed for native IGF-1 and hGH, mass-spectrometric methods for detecting MGF specifically have been reported in the doping-control literature, and athletes subject to WADA, USADA, UKAD, or equivalent frameworks should consider MGF and PEG-MGF categorically prohibited in and out of competition.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
MGF is the 'missing signal' that unlocks muscle growth beyond what training alone can produce.
Reality
MGF is one of many signals in the load-response cascade, not a master switch. Most published evidence is preclinical. Human synthetic-MGF trials demonstrating hypertrophy beyond what training alone produces are not available. The mechanism is interesting; the clinical demonstration is not there.
Myth
MGF is safer than LR3 because it is more 'natural' and only acts locally.
Reality
The endogenous IGF-1Ec splice variant occurs at specific local concentrations during mechanically gated muscle repair. Injecting 100–200 mcg of synthetic E-domain or IGF-1Ec into muscle is not physiologically equivalent. Safety framing based on endogenous occurrence is not well supported.
Myth
PEG-MGF is equivalent to MGF with longer duration — you can just use it less often.
Reality
PEG-MGF's extended half-life changes the pharmacologic regime from a pulse tied to acute mechanical load to a more sustained systemic exposure. Whether the satellite-cell-activating mechanism holds in that regime is debatable rather than demonstrated. Convenience does not equal equivalence.
Myth
Synthetic MGF solves the instability problem that limits native MGF.
Reality
Unmodified synthetic MGF is still highly unstable in solution. The instability problem is intrinsic to the peptide, not to its source. PEG-MGF addresses stability at the cost of changing the pharmacologic profile. The research-chemical market solves neither problem with QA-grade manufacturing.
Published Research
23 studiesThe emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
Mechanical growth factor inhibited syndesmophyte formation and the progression of osteoarthritis and ankylosing spondylitis-like symptoms in HLA-B27/Hu-β2m transgenic rats
The role of mechano growth factor in chondrocytes and cartilage defects: a concise review
The Roles of IGF-1 and MGF on Nerve Regeneration under Hypoxia- Ischemia, Inflammation, Oxidative Stress, and Physical Trauma
Potency of Full-Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations
Janssen et al., PLoS One 2016 — independent of the Goldspink programme (Erasmus MC, Charite, Cologne) and the most important correction to the safety framing. Full-length MGF directly activates IGF-1R (EC50 7.83 nM versus 0.86 nM for IGF-I) and both insulin receptor isoforms, while the isolated E-peptide does not. The reassurance that MGF bypasses IGF-1R applies only to the fragment, not to the full-length product.
Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls
Thevis et al., Growth Horm IGF Res 2014. The paper that retired the assumption that MGF is undetectable: a 12,264.9 Da full-length product characterized by nanoLC high-resolution tandem MS down to 0.25 ng/mL, implemented into routine peptide-hormone doping control. Note the scope — this method targets full-length MGF, while the short E-peptide sold as MGF is a separate analyte requiring separate assays.
Biological activity of the e domain of the IGF-1Ec as addressed by synthetic peptides
Ageing is associated with diminished muscle re-growth and myogenic precursor cell expansion early after immobility-induced atrophy in human skeletal muscle
Mechano-Growth Factor: an important cog or a loose screw in the repair machinery?
The nuclear localization of MGF receptor in osteoblasts under mechanical stimulation
[Expression of mechano-growth factor and its roles in tissue repairs and regeneration]
Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages
The closest thing to a human-cell demonstration of the mechanism behind post-workout MGF injection: the synthetic E peptide activates human muscle progenitor cells and raises their fusion potential across donor ages. It is an in-vitro result on isolated cells, not evidence that injecting the peptide into a trained muscle does the same thing in a person.
Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration
Matheny, Nindl and Adamo, Endocrinology 2010 — an independent, NIH-funded review and the single most important caveat on this page. Its point is not that MGF research is thin but that the peptide itself has never been found: no analogous peptide product of the IGF-1 gene has been identified in or isolated from cultured cells, their conditioned medium, or any in vivo animal tissue or biological fluid. The splicing event is real and widely replicated; the protein that injectable MGF is meant to imitate has not been shown to exist.
Coordinated increase in skeletal muscle fiber area and expression of IGF-I with resistance exercise in elderly post-operative patients
Effects of different intensities of resistance exercise on regulators of myogenesis
Muscle expressions of MGF, IGF-IEa, and myostatin in intact and hypophysectomized rats: effects of rhGH and testosterone alone or combined
Serum IGF-I levels and IGF-I gene splicing in muscle of healthy young males receiving rhGH
Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction
Quantitative histology and MGF gene expression in rats following SSC exercise in vivo
Impairment of IGF-I gene splicing and MGF expression associated with muscle wasting
The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men
Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation
Yang and Goldspink, FEBS Lett 2002 — the actual primary source for the claim, repeated across the peptide internet, that MGF works through a receptor other than IGF-1R. What the paper did was block IGF-1R with an antibody and observe that the E-domain still worked, which indicates a different receptor without identifying one. Two decades later nobody has.
Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch
Yang, Alnaqeeb, Simpson and Goldspink, J Muscle Res Cell Motil 1996. The paper that started all of this: stretched rabbit muscle expresses a second IGF-1 mRNA alongside the systemic one, which is the observation the entire mechano-growth-factor concept is built on. Every claim made for injectable MGF traces back here.
Quick Facts
- Class
- Growth Factor Splice Variant
- Tier
- D
- Evidence
- Emerging
- Safety
- Limited Data
- Updated
- Nov 2026
- Citations
- 23PubMed
Also known as
Tags
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.